- Home
- NETD vs IVA Comparison
NETD vs IVA Comparison
Compare NETD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NETD
- IVA
- Stock Information
- Founded
- NETD 2023
- IVA 2011
- Country
- NETD United States
- IVA France
- Employees
- NETD N/A
- IVA N/A
- Industry
- NETD
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- NETD
- IVA Health Care
- Exchange
- NETD Nasdaq
- IVA Nasdaq
- Market Cap
- NETD 422.4M
- IVA 359.6M
- IPO Year
- NETD 2023
- IVA 2020
- Fundamental
- Price
- NETD $11.25
- IVA $4.36
- Analyst Decision
- NETD
- IVA Strong Buy
- Analyst Count
- NETD 0
- IVA 4
- Target Price
- NETD N/A
- IVA $10.50
- AVG Volume (30 Days)
- NETD 65.3K
- IVA 29.2K
- Earning Date
- NETD 01-01-0001
- IVA 09-24-2025
- Dividend Yield
- NETD N/A
- IVA N/A
- EPS Growth
- NETD N/A
- IVA N/A
- EPS
- NETD 0.20
- IVA N/A
- Revenue
- NETD N/A
- IVA $14,591,573.00
- Revenue This Year
- NETD N/A
- IVA $44.22
- Revenue Next Year
- NETD N/A
- IVA $24.23
- P/E Ratio
- NETD $54.91
- IVA N/A
- Revenue Growth
- NETD N/A
- IVA N/A
- 52 Week Low
- NETD $10.58
- IVA $1.53
- 52 Week High
- NETD $11.47
- IVA $4.36
- Technical
- Relative Strength Index (RSI)
- NETD 57.25
- IVA 74.37
- Support Level
- NETD $11.20
- IVA $3.44
- Resistance Level
- NETD $11.24
- IVA $3.58
- Average True Range (ATR)
- NETD 0.02
- IVA 0.30
- MACD
- NETD -0.00
- IVA 0.11
- Stochastic Oscillator
- NETD 68.67
- IVA 100.00
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.